Picture loading failed.

Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Teclistamab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Teclistamab is an off-the-shelf, T-Cell redirecting, bispecific antibody targeting both BCMA and CD3 receptors. BCMA is expressed at high levels on multiple myeloma cells. 4,5,6,7,8. Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce killing of tumor cells.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-557-1mg 1mg Inquiry
GMP-Bios-ab-557-10mg 10mg Inquiry
GMP-Bios-ab-557-100mg 100mg Inquiry
GMP-Bios-ab-557-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Teclistamab biosimilar,Bispecific mAb)
INN Name Teclistamab
TargetTNFRSF17;CD3E
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCLambda;Lambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2018
Year Recommended2019
CompaniesGenmab;Janssen Research & Development
Conditions Approvedna
Conditions ActiveMultiple myeloma
Conditions Discontinuedna
Development Techna